CRRT and suggest loading and subsequent dosing
recommendations.(SA-PO3071, 11/18, 10:00 AM)
-- "Management of Severe Hyperkalemia with Continuous Veno-venous
Hemodialysis." Anjali Ganda and colleagues at Columbia University
conclude that continuous veno-venous hemodialysis (CVVHD) using high
dialysate flows may represent a safe and acceptable alternative to
traditional HD in the acute management of severe hyperkalemia (PUB385).
"It is exciting to see the increasing volume of clinician-initiated research activity focused on daily home hemodialysis and critical care therapy," said Jeff Burbank, CEO of NxStage Medical, Inc. "For daily home hemodialysis, in particular, this research reflects the growing presence of DHD in mainstream patient care, and deepens our understanding of this modality in both clinical and economic terms."
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of End Stage Renal Disease (ESRD) and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.
This release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. All statements
contained in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions
|SOURCE NxStage Medical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved